Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
VSU signs MoU with Malladi Drugs to make pharma students industry-ready
With the aim of providing students with quality education, technical knowledge and practical skills required in the pharmaceutical industry, Vikrama Simhapuri University (VSU), through its College of Pharmaceutical Sciences, Kavali, has entered…
Profit-booking drags Nifty below 25,200; Pharma holds firm as metals, durables bleed
Updated - November 18, 2026 at 01:27 PM. Benchmark indices fell sharply in mid-session trade on Wednesday, with broad-based profit-booking accelerating after the morning open. The Sensex was down 624.97 points or 0.76 per cent at 81,907.22 as of…
Royalty Pharma (NASDAQ:RPRX) Stock Price Target Raised at TD Cowen
Royalty Pharma (NASDAQ:RPRX - Get Free Report) had its price target hoisted by stock analysts at TD Cowen from $68.00 to $80.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a 'buy' rating on the…
SAGE Says: The Power of Purpose in Pharma Advertising
The pharmaceutical category is one of the most prolific TV advertisers, spending billions of dollars annually across linear and streaming CTV. We asked iSpot SAGE to dig up some of the most effective non-OTC pharma ads from the second half of this…
BridgeBio Pharma, Inc. $BBIO Shares Newly Bought by Aberdeen Group plc
Aberdeen Group plc purchased a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 301,848 shares of the…
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock Has Consensus Target Price of $36.25
Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) has received an average rating of 'Moderate Buy' from the six brokerages that are covering the company, MarketBeat reports. Two analysts have rated the stock with a sell rating, three have…
NewAmsterdam Pharma Sees Unusually Large Options Volume (NASDAQ:NAMS)
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) saw some unusual options trading on Tuesday. Traders acquired 7,505 call options on the company. This is an increase of approximately 962% compared to the typical volume of 707 call…
NewAmsterdam Pharma Sees Unusually High Options Volume (NASDAQ:NAMS)
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) was the target of some unusual options trading on Tuesday. Stock traders purchased 7,505 call options on the company. This is an increase of 962% compared to the typical volume of 707…
Avalyn Pharma (NASDAQ:AVLN) Share Price Crosses Below Fifty Day Moving Average on Analyst Downgrade
Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report) shares passed below its 50-day moving average during trading on Tuesday after Morgan Stanley lowered their price target on the stock from $57.00 to $53.00. The stock has a 50-day moving average of…
Stocks to watch, Nov 18: ArMee Info, IIFL Finance, RITES, Supreme Petrochem, Glenmark, Mankind Pharma, Ashok Buildcon, Advait Energy, Apollo Micro, Nykaa
RITES has entered into an MoU with National Mission for Clean Ganga [an authority under the Environment (Protection) Act, 1986 (EPA)]. This MoU will establish a long term working mechanism between RITES and NMCG to collaborate on the preparation of…
One Liberty Properties: Upgrade After Q3, As Industrial Portfolio Grows Selectively
Albert Anthony is the pen name of a business author on Amazon and a contributing analyst to investing platforms like Seeking Alpha since 2023, where he has over + 2,000 followers and has covered hundreds of stocks in multiple sectors including…
Nuix takeover offer caps off a wild six-year rollercoaster ride
It's almost exactly six years since Nuix debuted on the ASX with much fanfare, and now it looks as though the analytics and intelligence software group will be plucked off the exchange in the coming months. The Macquarie-backed business is just the…
Pfizer: The Patent Cliff Fears Are Overblown
Pfizer Inc., a Big Pharma player offering a 5.96% dividend yield, remains a controversial choice among long-term retail investors. Most concerns reflect PFE's upcoming patent expiration cycle, which is expected to last about 3 years. However, I…
Football Daily | From Cincinnati to Manchester: Pochettino in a hurry to paint town red
With his team mired in the relegation zone and a massive match at Liverpool this weekend, Mauricio Pochettino has been understandably busy since being appointed head coach of Manchester United. Unfortunately for Old Trafford regulars, the small…
Rupert approves? News Corp staff get free tickets to preview of new Murdoch movie
You have reached your maximum number of saved items. Remove items from your saved list to add more. You've used all of your gift articles. 3 more will become available on the 1st of every month. It's unclear whether Danny Boyle, who directed the…
Receive a Daily briefing on Pharma Industry News
Get Started